ADMA
ADMA Biologics, Inc.
Healthcare · Biotechnology · NGM
$7.92
Close 2026-05-28
✓ ETHICAL PASS

UNKNOWN MOAT
HIGH
Data Confidence: 100%
Full financial profile available
Market Cap
$1.8B
Trailing P/E
11.65
Forward P/E
7.50
Rev Growth
+15.9%
Profit Margin
32.4%
ROE
43.3%
Analyst Target
$17.50
Recommendation
NONE
About ADMA Biologics, Inc.

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Ethical Screen
Business ActivityPASS
Debt RatioN/A
Cash RatioN/A
Receivables RatioN/A
Revenue Ratio (0.00%)PASS
OverallPASS
Score Ethical: 64.7
Score Valuation: 78.5
Score Quality: 88.2
Score Combined: 65.1

Full Analysis

Opportunity scores, earnings history, insider transactions, institutional holders, analyst consensus, and more.

Unlock with Membership
Opportunity Scores
Valuation100.0
Quality100.0
Cash Flow39.7
Moat40.0
Balance Sheet0.0
Debt Purity50.0
Liquid Purity50.0
Rev Purity100.0
Compliance100.0
Tier: SILVER · Score: 55.0 · Rank: #863
Insider Transactions
No insider transaction data.
Top Institutional Holders
No institutional holder data.
Additional Fundamentals
Enterprise Value
$43.6B
Price/Book
4.72
Beta
0.823
Analysts
4
Total Revenue (TTM)
$509.9M
Total Debt
$97.7B
Short Ratio
2.62
Short % Float
0.1%
Employees
640

Elite Intelligence

Trade Consideration with position sizing, convergence signals, and risk analysis. Available to Elite members.

Upgrade to Elite
Trade Consideration
The Opportunity
Score 65.1 (P99 — top 1.1% of scored tickers). Unknown Moat. Ethical PASS. 4 analysts at None.
Price: $7.92 | Target: $16.75 (+111%)
Score
65
Moat
Unknown
Conviction
Standard
Upside
+111%
The Fundamentals
Revenue Growth+15.9%
Profit Margin32.4%
ROE43.3%
Forward P/E7.5
Market Cap$1.8B
Position Sizing Scenarios
Stop: $6.73 (-15%) | Entry: $7.92
SharesCostProfit to TargetR:R
To Consensus ($16.75, 4 analysts)
10$79.20+$88.30 (111%)7.4R
50$396.00+$441.50 (111%)7.4R
100$792.00+$883.00 (111%)7.4R
Risk Factors
  • No elevated risk flags in current data
The Verdict
ADMA Biologics, Inc. passes all ethical screens and holds a unknown competitive moat.
Quantitative Grade

A single score combining all analytical layers below. A is strongest, D is weakest.

D
Quant Score
30.2
Risk Grade
Layers
7
Risk Profile

How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.

VaR 95%
-5.1%
worst expected daily loss, 19 in 20 days
CVaR 95%
-9.0%
avg loss on the worst 5% of days
Annual Volatility
Sortino Ratio
-0.19
above 1.0 is good
Max Drawdown
-67.8%
Worst Day
Forward Outlook

Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.

30d Prob Up
90d Prob Up
Median Return 30d
Liquidity Score
80
Liquidity Grade
HIGHLY LIQUID
Trend & Momentum

What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?

Kalman Trend
Trend Strength
Momentum Signal
HMM Regime
RSI Signal
Technical Signals

Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.

MA Crossover
BELOW_200
Bollinger Position
LOWER_HALF
Beta
Relative Volume
0.4x
Short Interest
Financial Health

Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.

Altman Z-Score
below 1.81 = distress zone
Piotroski F-Score
Earnings Beat Rate
Earnings Consistency
Correlations

These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.

Most Correlated
TickerCorrelation
XZO0.370
VTI0.354
IWM0.352
XLC0.349
ESGU0.348
Inverse Correlated
TickerCorrelation
4911.T-0.191
NAVN-0.178
PCRX-0.162
QISI.QA-0.161
NAHO.AE-0.160
Seasonality

Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.

Best Day
Friday
Worst Day
Thursday
Best Month
Nov
Worst Month
May
Fri-Mon Effect
0.21182978038890593
Momentum Rankings

How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.

1M Return
-27.2%
3M Return
-47.8%
6M Return
-56.7%
12M Return
-60.1%
Momentum Rank
#4413
Momentum Signal
STRONG_DOWN

Get our daily market read free. Join thousands of traders.

Free Explorer Access